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share the same well-defined neurological picture, character-
ized by onset in the late second or early third decade of life
with a progressive, disabling, and drug-resistant action myo-
clonus and an invariably fatal course. The diagnosis is chal-
lenging until the full clinical picture is present. Progressive
myoclonus ataxia or epilepsy with SCARB2 mutations
should be distinguished from Unverricht-Lundborg disease,
myoclonic epilepsy with ragged-red fibers, Lafora body dis-
ease, the neuronal ceroid lipofuscinosis, sialidosis, dentato-
rubro-pallido-luysian atrophy,7 and myoclonus dystonia syn-
drome (DYT 11).
Legends to the Video
Video. The video shows the severe postural and intention
myoclonus.
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Young-Onset Parkinsonism due to
HomozygousDuplicationofa-Synuclein
in a Consanguineous Family
With a growing list of monogenetic causes of Parkin-
son’s disease (PD),1–3 prioritization of genetic testing is
made on the presumed mode of inheritance. In patients with
early-onset PD from consanguineous families, the most com-
mon mode of inheritance is autosomal recessive. Rarely, an
individual may be homozygous for a mutation inherited in
an autosomal dominant manner, complicating the diagnostic
process.
The proband is a 36-year-old female from a consan-
guineous Pakistani family (Fig. 1A). She presented with a
5-year history of left-sided stiffness, micrographia, festi-
nant gait, tremor, and falls. Past medical history included
postpartum psychosis and severe depression. There were
no symptoms of autonomic dysfunction. Neurological
examination at the age of 35 years revealed severe bilat-
eral bradykinesia, rigidity, worse on the left, and mild
bilateral upper limb rest tremor. Gait was shuffling, with
freezing and complete loss of postural reflexes. Bilateral
ankle clonus was noted. Initially, there was a poor
response to dopamine agonists. She responded well to
100/25 mg co-careldopa 3 times per day, but developed
wearing offs and peak-dose dyskinesias after 4 months of
treatment. There was no family history of parkinsonism.
The proband’s mother’s neurological examination at the
age of 72 years was normal. The proband’s father, who
died at age 64 years from a stroke, had no symptoms or
signs of parkinsonism as described by his family. Her sib-
lings and children were asymptomatic, but were unavail-
able for examination.
Investigations in the proband included routine blood
work, copper studies, and white cell enzymes, and were all
normal. Dopamine transporter scan (DAT-SCAN) showed
bilateral reduction in tracer uptake in the striatum, more sig-
nificant on the right. Formal neuropsychological examina-
tion revealed a mild degree of intellectual under-functioning
from premorbid estimates, with anterior/subcortical dysfunc-
tion. Mutations in PARKIN, PINK1, and common LRRK2
mutations were excluded. Multiplex ligation-dependent
probe amplification (MLPA) showed 4 copies of SNCA
(Fig. 1B). Comparative genomic hybridization (Nimblegen
135 K array Roche-Niblegen) showed copy number gain of
0.928 Mb, containing 5 genes including SNCA (Fig. 1C).
Single-nucleotide polymorphism (SNP) array showed this to
be homozygous. Fluorescent in situ-hybridization
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demonstrated duplication of SNCA on both alleles (Supple-
mental Figure 1). The proband’s mother’s MLPA showed
SNCA duplication. Considering the proband’s homozygosity
for SNCA duplication, her father is likely to have had an
SNCA duplication. Less likely, de novo duplication (in addi-
tion to duplication inherited from mother) occurred in the
proband.
SNCA multiplication is a rare cause of autosomal domi-
nant PD.4,5 SNCA triplications (4 copies of SNCA) are fully
penetrant; with early-onset and rapidly progressive parkin-
sonism associated with dementia, autonomic dysfunction,
and psychiatric features.4 With SNCA duplications (3 SNCA
copies), the disease clinically resembles idiopathic PD5 and
reduced penetrance is recognized.6 Our patient has 4 SNCA
copies and her clinical phenotype closely matches that
of patients with SNCA triplications4 and is in keeping
with the single previously described case of SNCA double
duplication.7
Homozygous SNCA duplications are a rare cause of
young-onset parkinsonism and should be considered in the
patients with a family history compatible with recessive
inheritance. Early cognitive dysfunction and depression are
consistently reported in patients with 4 SNCA copies and
may be regarded as ‘‘red flags’’ for SNCA multiplications.
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NIHR Biomedical Research Centres funding scheme.
FIG. 1. A: Pedigree and clinical information on the family. A half filled symbol represents the proband (arrow), who is the only individual affected by
parkinsonism. Clinically unaffected but confirmed mutation carrier (the proband’s mother) is represented by a circle with a dot. Empty symbols rep-
resent clinically unaffected family members. B: MLPA result for the proband, shows triplication of exons 1, 3, 4, 5, and 6 of SNCA (exon 2 result not
shown) using kit P052C, with an MLPA ratio of approximately 2.0 (normal MLPA ratio is 1.0, with 0.5 for each allele), indicating 4 copies of SNCA.
C: The proband’s array–comparative genomic hybridization (array-CGH) result shows a region of copy number gain on the long arm of chromosome
4 within band 4q22.1. The copy number gain is approximately 0.98 Mb and contains 5 genes including SNCA. A normal ratio plot score for any
given gene is zero, the average ratio score in this region of copy number gain is 1.0, consistent with the MLPA finding of 4 copies of the SNCA
gene region. SNP array (not shown) showed that the duplicated regions on 4q22 were homozygous. Supplemental Figure 1. FISH analysis of inter-
phase chromosomes from EBV-transformed lymphocytes of the proband. There are two FISH probes shown, both from the critical region (4q22).
The green probe (RP11-67M1) shows two pairs of signals for each chromosome 4 indicating a double duplication. The red probe (RP11-169K7) also
shows two signals for each chromosome 4 and an additional two signals due to cross-hybridization to another chromosome.
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Tremor-Ataxia With Central
Hypomyelination (TACH):
Dystonia as a New Clinical
Feature
Leukodystrophies are a group of inherited neurodege-
nerative disorders characterized by abnormal white matter
on brain imaging. They can be classified as demyelinating or
hypomyelinating based on MRI features.1 Tremor-ataxia
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with central hypomyelination (TACH) is a novel autosomal
recessive hypomyelinating leukodystrophy.2 TACH and 3
other clinically similar disorders—leukodystrophy with oli-
godontia, 4H syndrome (hypomyelination, hypodontia, and
hypogonatrophic hypogonadism), and hypomyelination with
cerebellar atrophy and hypoplasia of the corpus callosum—
have been shown to be caused by mutations in POLR3A
and POLR3B.3–5
The clinical features of TACH have thus far been charac-
terized by tremor, motor regression, spasticity, ataxia, dys-
arthria, abnormal ocular saccades and/or pursuits, gaze-
evoked nystagmus, and optic atrophy.2 The average age of
onset is 2.5 years, and the average age of the need for a
wheelchair is 7.3 years.2 We report dystonia as a new clini-
cal feature of TACH in 1 patient from the initial manuscript
reporting POLR3A mutations in TACH, LO, and 4H
syndrome.3
The patient was born at term to nonconsanguineous,
healthy parents of French- and English-Canadian origin. He
presented at 2 years of age with an intention tremor and
unsteady gait, then subsequently developed progressive
ataxia, dysarthria, and spasticity, requiring the use of a
wheelchair at 5 years. Cognition appeared largely spared
until later in the course. His dentition was normal, and there
was no evidence of hypogonadism.
The patient’s brain MRIs revealed a hypomyelinating leu-
kodystrophy1–3 with posterior white matter atrophy and fea-
tures similar to what is seen in 4H6: hypointensities of the
dentate nuclei, anterolateral nuclei of the thalami, and optic
radiations (Fig. 1). Sequencing of the POLR3A gene
revealed 2 pathogenic missense mutations, 1 inherited from
each parent: c.1674C>G (p.Phe558Leu) and c.3742insACC
(p.1248insThr).3
At the time of his last visit, the patient was 10 years old.
The neurological examination was significant for abnormal
smooth pursuits, gaze-evoked nystagmus, spastic quadrapa-
resis, ataxia, dysmetria, and dysdiadochokinesia. He also
presented generalized dystonia that intermittently fluctuated
(Video 1). On further questioning, this symptom had insidi-
ously appeared at least a few years prior. As per the parents’
request, no medication was given and therefore response to
treatment could not be assessed. Of note, the patient had
never taken any D2-receptor blockers such as antipsychotic
or antiemetic medications.
Although this is the first description of dystonia in a Pol
III-related leukodystrophy, dystonia has been described in
other leukodystrophies such as Pelizaeus–Merzbacher dis-
ease, hypomyelination with atrophy of the basal ganglia and
cerebellum, leukoencephalopathy with dystonia and motor
neuropathy, and leukoencephalopathy with brain stem and
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